Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:34:07.849Z.
Calculation as of: 2026-10-06T17:34:07.849Z.
Quote observation: 2026-10-06T17:30:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0bb308cc02f92ae7022b98057b1ab9be430f0ff9c4f6ee28c48a1717489dc78b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$472.33M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$473.58M
Price/FCF Ratio
N/A
TTM Avg
826.37
3Y Avg
710.39
5Y Avg
710.39
Market Cap
$473.65M
Price/FCF Ratio
N/A
TTM Avg
26.42
3Y Avg
26.42
5Y Avg
26.42
Market Cap
$484.56M
Price/FCF Ratio
11.79
TTM Avg
8.08
3Y Avg
11.34
5Y Avg
14.47
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | $466.84M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $469.70M | 17.74 | 24.31 | 87.97 | 67.12 |
| Alpha Teknova, Inc. (TKNO)vs › | $471.27M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.33M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $473.58M | N/A | 826.37 | 710.39 | 710.39 |
| Arvinas, Inc. (ARVN)vs › | $473.59M | N/A | 5.51 | 5.54 | 11.44 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.65M | N/A | 26.42 | 26.42 | 26.42 |
| NRC Health (NRC)vs › | $457.83M | 21.16 | 27.39 | 28.55 | 30.18 |
| Puma Biotechnology, Inc. (PBYI)vs › | $484.56M | 11.79 | 8.08 | 11.34 | 14.47 |
| Evolus, Inc. (EOLS)vs › | $486.67M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
